Background: Cardiac involvement in dengue has been increasingly recognized, yet the true burden and spectrum of arrhythmias remain uncertain due to heterogeneous and fragmented evidence. We conducted a systematic review and meta-analysis to estimate the proportion of cardiac arrhythmias in patients with dengue and to describe the distribution of major arrhythmia subtypes. Methods: We searched PubMed/MEDLINE, EMBASE, LILACS, Global Index Medicus, and Google Scholar from inception to November 2025 without language restrictions. Observational studies reporting the number of dengue patients evaluated for arrhythmias and the number with at least one rhythm disturbance were included. Random-effects generalized linear mixed models with a logit transformation were used to estimate pooled proportion with 95% confidence intervals (CIs). Subgroup analyses were performed by age group. Risk of bias was assessed using the Joanna Briggs Institute tool, and certainty of evidence was evaluated with GRADE. Results: Thirty-five studies, including 6948 patients, were analyzed. The pooled proportion of any arrhythmia was 24.48% (95% CI 17.54–33.07), with a higher proportion in adults (30.00%) than in children (10.73%). Sinus bradycardia (11.84%) and sinus tachycardia (10.63%) were the most frequent abnormalities. Atrioventricular block was uncommon (1.33%). Between-study heterogeneity was high for most outcomes. No significant small-study effects were detected. Conclusions: Cardiac arrhythmias occur in approximately one in four patients with dengue, predominantly as sinus rate abnormalities. While often transient, these findings support the role of baseline and risk-based ECG monitoring, particularly in hospitalized adults and patients with severe disease.

Background/Objectives: Solanezumab is a humanized monoclonal antibody designed to bind soluble amyloid-beta (Aβ) and facilitate its clearance from the brain, aiming to slow the progression of Alzheimer’s disease (AD). Methods: A systematic search was applied in four medical databases through October 2024 to identify phase 2 or 3 randomized controlled trials evaluating solanezumab in patients aged ≥50 years with mild AD or in preclinical stages. The primary outcomes were changes in cognitive and functional scales, including ADAS-cog14, MMSE, ADCS-ADL, and CDR-SB. Data were pooled using a random-effects model, and certainty of evidence was assessed using GRADE. Results: Seven trials involving 4181 participants were included. Solanezumab did not significantly reduce cognitive decline based on ADAS-cog14 (MD = −0.75; 95% CI: −2.65 to 1.15; very low certainty) or improve functional scores on ADCS-ADL (MD = 0.85; 95% CI: −1.86 to 3.56; very low certainty) and CDR-SB (MD = −0.15; 95% CI: −0.89 to 0.60; very low certainty). A modest but statistically significant improvement was observed in MMSE scores (MD = 0.59; 95% CI: 0.33 to 0.86; moderate certainty). Conclusions: While solanezumab may offer slight benefits in general cognitive performance, its overall impact on clinically meaningful outcomes remains limited. The results do not support its use as a disease-modifying therapy for Alzheimer’s disease in either preclinical or symptomatic stages.

We sincerely thank Iqhrammullah and Rampengan for their thoughtful and valuable Comment